179 related articles for article (PubMed ID: 21698147)
1. Up-regulated Dicer expression in patients with cutaneous melanoma.
Ma Z; Swede H; Cassarino D; Fleming E; Fire A; Dadras SS
PLoS One; 2011; 6(6):e20494. PubMed ID: 21698147
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
[TBL] [Abstract][Full Text] [Related]
3. Mutation Scanning of D1705 and D1709 in the RNAse IIIb Domain of MicroRNA Processing Enzyme Dicer in Cutaneous Melanoma.
Sand M; Bechara FG; Skrygan M; Sand D; Gambichler T; Bromba M; Stockfleth E; Hessam S
Pathol Oncol Res; 2016 Jul; 22(3):639-41. PubMed ID: 26683837
[TBL] [Abstract][Full Text] [Related]
4. Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion.
Jafarnejad SM; Ardekani GS; Ghaffari M; Martinka M; Li G
Oncogene; 2013 Apr; 32(17):2131-9. PubMed ID: 22689055
[TBL] [Abstract][Full Text] [Related]
5. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi.
Sand M; Skrygan M; Georgas D; Sand D; Gambichler T; Altmeyer P; Bechara FG
Cell Tissue Res; 2012 Oct; 350(1):119-26. PubMed ID: 22706980
[TBL] [Abstract][Full Text] [Related]
6. Expression levels of the microRNA processing enzymes Drosha and dicer in epithelial skin cancer.
Sand M; Gambichler T; Skrygan M; Sand D; Scola N; Altmeyer P; Bechara FG
Cancer Invest; 2010 Jul; 28(6):649-53. PubMed ID: 20210522
[TBL] [Abstract][Full Text] [Related]
7. Dicer is down-regulated in clear cell renal cell carcinoma and in vitro Dicer knockdown enhances malignant phenotype transformation.
Ma X; Fan Y; Gao Y; Zhang Y; Huang Q; Ai Q; Ni D; Chen W; Zhang P; Song E; Wang B; Shi T; Zheng T; Zhang X
Urol Oncol; 2014 Jan; 32(1):46.e9-17. PubMed ID: 24094887
[TBL] [Abstract][Full Text] [Related]
8. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.
Sand M; Skrygan M; Sand D; Georgas D; Gambichler T; Hahn SA; Altmeyer P; Bechara FG
Cell Tissue Res; 2013 Jan; 351(1):85-98. PubMed ID: 23111773
[TBL] [Abstract][Full Text] [Related]
9. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
10. Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas.
Prodromaki E; Korpetinou A; Giannopoulou E; Vlotinou E; Chatziathanasiadou Μ; Papachristou NI; Scopa CD; Papadaki H; Kalofonos HP; Papachristou DJ
Cell Oncol (Dordr); 2015 Aug; 38(4):307-17. PubMed ID: 26227789
[TBL] [Abstract][Full Text] [Related]
11. The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma.
Guo X; Liao Q; Chen P; Li X; Xiong W; Ma J; Li X; Luo Z; Tang H; Deng M; Zheng Y; Wang R; Zhang W; Li G
J Cancer Res Clin Oncol; 2012 Jan; 138(1):49-56. PubMed ID: 21953080
[TBL] [Abstract][Full Text] [Related]
12. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
[TBL] [Abstract][Full Text] [Related]
13. Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer.
Erler P; Keutgen XM; Crowley MJ; Zetoune T; Kundel A; Kleiman D; Beninato T; Scognamiglio T; Elemento O; Zarnegar R; Fahey TJ
Surgery; 2014 Dec; 156(6):1342-50; discussion 1350. PubMed ID: 25456905
[TBL] [Abstract][Full Text] [Related]
14. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Keller-Melchior R; Schmidt R; Piepkorn M
J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
[TBL] [Abstract][Full Text] [Related]
15. Aberrations in the micro-RNA biogenesis machinery and the emerging roles of micro-RNAs in the pathogenesis of cutaneous malignant melanoma.
Leibowitz-Amit R; Sidi Y; Avni D
Pigment Cell Melanoma Res; 2012 Nov; 25(6):740-57. PubMed ID: 22958787
[TBL] [Abstract][Full Text] [Related]
16. The modulation of Dicer regulates tumor immunogenicity in melanoma.
Hoffend NC; Magner WJ; Tomasi TB
Oncotarget; 2016 Jul; 7(30):47663-47673. PubMed ID: 27356752
[TBL] [Abstract][Full Text] [Related]
17. Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.
Babapoor S; Wu R; Kozubek J; Auidi D; Grant-Kels JM; Dadras SS
Lab Invest; 2017 Jun; 97(6):636-648. PubMed ID: 28218741
[TBL] [Abstract][Full Text] [Related]
18. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma.
Kitago M; Martinez SR; Nakamura T; Sim MS; Hoon DS
Clin Cancer Res; 2009 May; 15(9):2988-94. PubMed ID: 19336521
[TBL] [Abstract][Full Text] [Related]
19. miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma.
Mueller DW; Rehli M; Bosserhoff AK
J Invest Dermatol; 2009 Jul; 129(7):1740-51. PubMed ID: 19212343
[
